In This Article:
Key Insights
-
Barinthus Biotherapeutics will host its Annual General Meeting on 10th of May
-
Salary of US$610.0k is part of CEO Bill Enright's total remuneration
-
The overall pay is 54% above the industry average
-
Barinthus Biotherapeutics' three-year loss to shareholders was 84% while its EPS grew by 40% over the past three years
In the past three years, the share price of Barinthus Biotherapeutics plc (NASDAQ:BRNS) has struggled to grow and now shareholders are sitting on a loss. What is concerning is that despite positive EPS growth, the share price has not tracked the trend in fundamentals. The AGM coming up on the 10th of May could be an opportunity for shareholders to bring these concerns to the board's attention. They could also try to influence management and firm direction through voting on resolutions such as executive remuneration and other company matters. Here's our take on why we think shareholders may want to be cautious of approving a raise for the CEO at the moment.
Check out our latest analysis for Barinthus Biotherapeutics
How Does Total Compensation For Bill Enright Compare With Other Companies In The Industry?
According to our data, Barinthus Biotherapeutics plc has a market capitalization of US$83m, and paid its CEO total annual compensation worth US$1.8m over the year to December 2023. We note that's a decrease of 13% compared to last year. We think total compensation is more important but our data shows that the CEO salary is lower, at US$610k.
On comparing similar-sized companies in the American Biotechs industry with market capitalizations below US$200m, we found that the median total CEO compensation was US$1.2m. Accordingly, our analysis reveals that Barinthus Biotherapeutics plc pays Bill Enright north of the industry median. What's more, Bill Enright holds US$5.4m worth of shares in the company in their own name, indicating that they have a lot of skin in the game.
| Component | 2023 | 2022 | Proportion (2023) |
| Salary | US$610k | US$569k | 34% |
| Other | US$1.2m | US$1.5m | 66% |
| Total Compensation | US$1.8m | US$2.1m | 100% |
Speaking on an industry level, nearly 23% of total compensation represents salary, while the remainder of 77% is other remuneration. Barinthus Biotherapeutics is paying a higher share of its remuneration through a salary in comparison to the overall industry. It's important to note that a slant towards non-salary compensation suggests that total pay is tied to the company's performance.
A Look at Barinthus Biotherapeutics plc's Growth Numbers
Barinthus Biotherapeutics plc's earnings per share (EPS) grew 40% per year over the last three years. It saw its revenue drop 98% over the last year.